Stem cell therapy for heart failure: Ensuring regenerative proficiency

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Patient-derived stem cells enable promising regenerative strategies, but display heterogenous cardiac reparative proficiency, leading to unpredictable therapeutic outcomes impeding practice adoption. Means to establish and certify the regenerative potency of emerging biotherapies are thus warranted. In this era of clinomics, deconvolution of variant cytoreparative performance in clinical trials offers an unprecedented opportunity to map pathways that segregate regenerative from non-regenerative states informing the evolution of cardio-regenerative quality systems. A maiden example of this approach is cardiopoiesis-mediated lineage specification developed to ensure regenerative performance. Successfully tested in pre-clinical and early clinical studies, the safety and efficacy of the cardiopoietic stem cell phenotype is undergoing validation in pivotal trials for chronic ischemic cardiomyopathy offering the prospect of a next-generation regenerative solution for heart failure.

Original languageEnglish (US)
JournalTrends in Cardiovascular Medicine
DOIs
StateAccepted/In press - 2016

Fingerprint

Cell- and Tissue-Based Therapy
Stem Cells
Heart Failure
Biological Therapy
Cardiomyopathies
Clinical Trials
Phenotype
Safety
Therapeutics
Clinical Studies

Keywords

  • Cardiopoiesis
  • Cardiopoietic stem cell
  • Cardiovascular disease
  • Clinical trial
  • Clinomics
  • Epidemic
  • Health care
  • Myocardial infarction
  • Next generation
  • Quality
  • Regenerative medicine
  • System

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{2150570f3bb945b6b9d19778e88e789b,
title = "Stem cell therapy for heart failure: Ensuring regenerative proficiency",
abstract = "Patient-derived stem cells enable promising regenerative strategies, but display heterogenous cardiac reparative proficiency, leading to unpredictable therapeutic outcomes impeding practice adoption. Means to establish and certify the regenerative potency of emerging biotherapies are thus warranted. In this era of clinomics, deconvolution of variant cytoreparative performance in clinical trials offers an unprecedented opportunity to map pathways that segregate regenerative from non-regenerative states informing the evolution of cardio-regenerative quality systems. A maiden example of this approach is cardiopoiesis-mediated lineage specification developed to ensure regenerative performance. Successfully tested in pre-clinical and early clinical studies, the safety and efficacy of the cardiopoietic stem cell phenotype is undergoing validation in pivotal trials for chronic ischemic cardiomyopathy offering the prospect of a next-generation regenerative solution for heart failure.",
keywords = "Cardiopoiesis, Cardiopoietic stem cell, Cardiovascular disease, Clinical trial, Clinomics, Epidemic, Health care, Myocardial infarction, Next generation, Quality, Regenerative medicine, System",
author = "Andre Terzic and Atta Behfar",
year = "2016",
doi = "10.1016/j.tcm.2016.01.003",
language = "English (US)",
journal = "Trends in Cardiovascular Medicine",
issn = "1050-1738",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Stem cell therapy for heart failure

T2 - Ensuring regenerative proficiency

AU - Terzic, Andre

AU - Behfar, Atta

PY - 2016

Y1 - 2016

N2 - Patient-derived stem cells enable promising regenerative strategies, but display heterogenous cardiac reparative proficiency, leading to unpredictable therapeutic outcomes impeding practice adoption. Means to establish and certify the regenerative potency of emerging biotherapies are thus warranted. In this era of clinomics, deconvolution of variant cytoreparative performance in clinical trials offers an unprecedented opportunity to map pathways that segregate regenerative from non-regenerative states informing the evolution of cardio-regenerative quality systems. A maiden example of this approach is cardiopoiesis-mediated lineage specification developed to ensure regenerative performance. Successfully tested in pre-clinical and early clinical studies, the safety and efficacy of the cardiopoietic stem cell phenotype is undergoing validation in pivotal trials for chronic ischemic cardiomyopathy offering the prospect of a next-generation regenerative solution for heart failure.

AB - Patient-derived stem cells enable promising regenerative strategies, but display heterogenous cardiac reparative proficiency, leading to unpredictable therapeutic outcomes impeding practice adoption. Means to establish and certify the regenerative potency of emerging biotherapies are thus warranted. In this era of clinomics, deconvolution of variant cytoreparative performance in clinical trials offers an unprecedented opportunity to map pathways that segregate regenerative from non-regenerative states informing the evolution of cardio-regenerative quality systems. A maiden example of this approach is cardiopoiesis-mediated lineage specification developed to ensure regenerative performance. Successfully tested in pre-clinical and early clinical studies, the safety and efficacy of the cardiopoietic stem cell phenotype is undergoing validation in pivotal trials for chronic ischemic cardiomyopathy offering the prospect of a next-generation regenerative solution for heart failure.

KW - Cardiopoiesis

KW - Cardiopoietic stem cell

KW - Cardiovascular disease

KW - Clinical trial

KW - Clinomics

KW - Epidemic

KW - Health care

KW - Myocardial infarction

KW - Next generation

KW - Quality

KW - Regenerative medicine

KW - System

UR - http://www.scopus.com/inward/record.url?scp=84962159429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962159429&partnerID=8YFLogxK

U2 - 10.1016/j.tcm.2016.01.003

DO - 10.1016/j.tcm.2016.01.003

M3 - Article

C2 - 27020904

AN - SCOPUS:84962159429

JO - Trends in Cardiovascular Medicine

JF - Trends in Cardiovascular Medicine

SN - 1050-1738

ER -